RxDoctor Payments Data

Diane Thomas, MD

Family Medicine · Sparks, NVNPI 1124006044

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 33 payments — averaging $47.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$414
  • AstraZeneca$341
  • Boehringer Ingelheim$234
  • Novo Nordisk$128
  • Edwards Lifesciences$103
  • Sanofi-aventis U.S. LLC$76
  • plus $260 from 8 others

What the payments were for

  • Food & beverage$1,550100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,556 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$26,161
Medicare patients
93
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$48,946
Nurtec OdtRimegepant Sulfate13$25,168
Atorvastatin Calcium134$2,025
SynthroidLevothyroxine Sodium19$1,977
Rosuvastatin Calcium72$1,534
Levothyroxine Sodium97$984
Duloxetine Hcl30$866
Ezetimibe43$800
Potassium Chloride23$613
Lisinopril66$569
Alendronate Sodium35$540
Bupropion XlBupropion Hcl14$487
Montelukast Sodium37$463
Trazodone Hcl35$438
Escitalopram Oxalate23$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$128$48,94624 claims
AbbVieSynthroid$414$1,97719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.

Other family medicine in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →